Literature DB >> 15504874

Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.

Kim L Credito1, Peter C Appelbaum.   

Abstract

Agar dilution MIC was used to compare activities of OPT-80, linezolid, vancomycin, teicoplanin, quinupristin/dalfopristin, amoxicillin/clavulanate, imipenem, clindamycin, and metronidazole against 350 gram-positive and -negative anaerobes. OPT-80 was active against gram-positive strains only, especially Clostridium spp. (85 strains tested, including 21 strains of C. difficile), with MICs ranging between </=0.016 and 0.25 microg/ml.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15504874      PMCID： PMC525447          DOI： 10.1128/AAC.48.11.4430-4434.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Clostridium difficile-associated diarrhea and colitis.

Authors:  S F Yassin; T M Young-Fadok; N N Zein; D S Pardi
Journal:  Mayo Clin Proc       Date:  2001-07       Impact factor: 7.616

2.  Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals.

Authors:  Mark A Miller; Meagan Hyland; Marianna Ofner-Agostini; Marie Gourdeau; Magued Ishak
Journal:  Infect Control Hosp Epidemiol       Date:  2002-03       Impact factor: 3.254

Review 3.  Diarrhea in developed and developing countries: magnitude, special settings, and etiologies.

Authors:  R L Guerrant; J M Hughes; N L Lima; J Crane
Journal:  Rev Infect Dis       Date:  1990 Jan-Feb

Review 4.  Diagnosis and treatment of Clostridium difficile colitis.

Authors:  R Fekety; A B Shah
Journal:  JAMA       Date:  1993-01-06       Impact factor: 56.272

Review 5.  Clostridium difficile colitis.

Authors:  C P Kelly; C Pothoulakis; J T LaMont
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

6.  Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity.

Authors:  R J Theriault; J P Karwowski; M Jackson; R L Girolami; G N Sunga; C M Vojtko; L J Coen
Journal:  J Antibiot (Tokyo)       Date:  1987-05       Impact factor: 2.649

7.  In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile.

Authors:  R N Swanson; D J Hardy; N L Shipkowitz; C W Hanson; N C Ramer; P B Fernandes; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 8.  Antibiotic-associated diarrhea.

Authors:  J G Bartlett
Journal:  Clin Infect Dis       Date:  1992-10       Impact factor: 9.079

9.  In vitro activity of OPT-80 against Clostridium difficile.

Authors:  Grit Ackermann; Birgit Löffler; Daniela Adler; Arne C Rodloff
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

10.  Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC).

Authors: 
Journal:  MMWR Recomm Rep       Date:  1995-09-22
View more
  33 in total

Review 1.  Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.

Authors:  Dhara Shah; Minh-Duc Dang; Rodrigo Hasbun; Hoonmo L Koo; Zhi-Dong Jiang; Herbert L DuPont; Kevin W Garey
Journal:  Expert Rev Anti Infect Ther       Date:  2010-05       Impact factor: 5.091

2.  Fidaxomicin: in Clostridium difficile infection.

Authors:  Sean T Duggan
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

3.  In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp.

Authors:  Douglas J Biedenbach; James E Ross; Shannon D Putnam; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

Review 4.  Future novel therapeutic agents for Clostridium difficile infection.

Authors:  Hoonmo L Koo; Kevin W Garey; Herbert L Dupont
Journal:  Expert Opin Investig Drugs       Date:  2010-07       Impact factor: 6.206

5.  Antipropionibacterial activity of BAL19403, a novel macrolide antibiotic.

Authors:  Stefanie Heller; Laurenz Kellenberger; Stuart Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

6.  Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses.

Authors:  Y K Shue; P S Sears; S Shangle; R B Walsh; C Lee; S L Gorbach; F Okumu; R A Preston
Journal:  Antimicrob Agents Chemother       Date:  2008-02-11       Impact factor: 5.191

7.  Antianaerobic activity of sulopenem compared to six other agents.

Authors:  Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

8.  Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile.

Authors:  Farah Babakhani; Jaime Seddon; Pamela Sears
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

9.  OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection.

Authors:  Thomas J Louie; Judy Emery; Walter Krulicki; Brendan Byrne; Manuel Mah
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

10.  Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection.

Authors:  T Louie; M Miller; C Donskey; K Mullane; E J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.